Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Secondary Progressive Multiple Sclerosis (China)
CTR20254664Phase 3Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Remibrutinib (LOU064) with Placebo (2 arms). Primary endpoint: Time to 6-month confirmed disability progression (6mCDP) based on EDSS. Started Apr 2026; status: active.
02
Drugs
remibrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on CTR20254664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254664.